The effect of gelling ion on alginate microcapsule size and encapsulated islet efficacy for treating type 1 diabetes

Ariel Dalisay1, Michael Alexander1, Grace Kummerfeld1, Antonio Flores1, Ka-Hei Chan1, Rahul Krishnan1 and Jonathan RT Lakey1,2*

1Department of Surgery, University of California, Irvine, Orange, USA
2Department of Biomedical Engineering, University of California, Irvine, Irvine, USA

Abstract

Transplantation of alginate-encapsulated islets has the potential to treat patients suffering from type I diabetes, a condition characterized by an autoimmune attack against insulin-secreting beta cells. However, there are multiple challenges associated with this procedure, all of which must be adequately addressed prior to translation from trials in small animal and non-human primate models to human clinical trials. The lack of standardization of significant parameters of encapsulation device design and manufacture (i.e. purification protocols, surface-modification grafting techniques, alginate composition modifications) between labs is yet another obstacle that must be overcome before a clinically effective and applicable protocol for encapsulating islets can be implemented. The response of these microcapsules to long-term culture at physiological conditions has not been studied. In this study, alginate microcapsules were polymerized with either barium or calcium, to evaluate their morphological responses in order to choose an optimal gelling ion for future utilization in islet transplantation. We used two variation of alginites: high mannuronate (UPLVM) and high guluronate (UPLVG) alginate. Both barium and calcium crosslinked encapsulated islets successfully restore glucose control in diabetic athymic nude mice. Because the capsule size change overtime is significant, it's important to take this into account when choosing which alginate and which gelling ion will be used to make the capsules, to make sure that the end size is as intended to minimize hypoxic cores of the encapsulated islets, instead of just relying on capsule size immediately after polymerization. Our results showed that compared to the standard calcium ions, barium ions used for crosslinking alginate resulted in smaller size change of UPLVM capsules, thus maintaining the porosity and permeability.

Introduction

Type 1 diabetes is characterized by the autoimmune mediated destruction of beta cells in the pancreas. Since these cells produce the hormone insulin, which is required to maintain control over blood glucose level by inducing uptake of glucose from the blood into cells, lack of insulin in type 1 diabetes leads to high blood glucose levels, and susceptibility to tissue damage, amputation, blindness, and death [1,2]. Over the last decade, human islet transplantation has emerged as a viable alternative to conventional management strategies to treat type 1 diabetes. With appropriate immunosuppression regimens, patients that are able to remain insulin independent for up to 8 years post-transplant [3,4]. However, immunosuppression itself has several side effects, including susceptibility to infection, and toxicity to the transplanted islets. In the end, this leads to the search of technology to protect transplanted islets against rejection while minimizing or eliminating the requirement for immunosuppression [5].

Encapsulation of islets within biocompatible hydrogels is a solution proposed by biomedical engineers to address this uniquely frustrating issue. Cell encapsulation involves enveloping cells in a selectively permeable biocompatible matrix that allows for the diffusion of oxygen and nutrients but is able to effectively prevent immune cells and antibodies from reaching the graft, thus delaying rejection [6]. Encapsulation can be employed as a platform to deliver localized immunosuppression at the transplant site, thus avoiding the adverse effects of chronic systemic immunosuppression and can also be used to deliver nutrients and biological agents that will enhance islet survival and function after transplantation into patients [7,8]. While it is clear that encapsulation has several advantages over conventional islet transplantation, several roadblocks currently prevent translation of results from small animal and primate trials to human trials. Alginate pore size is a crucial parameter that aids in the protection of islets from host immune recognition, while allowing insulin, oxygen, and other micronutrients to diffuse through the capsules. Islet encapsulation within alginate hydrogels is advantageous because it prevents direct contact between the encapsulated islets and the host immune system while significantly reducing the need for chronic systemic immunosuppression [2,9]. Although several studies have demonstrated the utility of alginate microencapsulation in islet and stem cell transplantation [10], the response of these microcapsules to long-term culture at physiological conditions has hitherto not been evaluated. It is believed that alginate microcapsules exhibit isotropic shrinking at high culture temperatures and isotropic swelling in the presence of sodium ions. In this study, we evaluated various gelling ions and alginites to study their responses at specific temperatures and at physiological sodium ion concentrations to develop strategies to mitigate sodium ion-induced isotropic swelling of the alginate capsules.
Materials and methods

Effect of gelling ion type and concentration on microcapsule size

Aqueous solutions of ultra-pure low viscosity mannuronate (UPLVM, NovaMatrix® PRONOVA™) and ultra-pure low viscosity guluronate (UPLVG, NovaMatrix® PRONOVA™) at 2.5% w/v were used to generate alginate microcapsules using a compressed air-driven electrostatic encapsulator (Nisco Engineering AG). Standard settings of 4 psi (pressure), 80 rpm (agitator speed), 30 mm (needle height) and 25 G (needle height) were used. Three different divalent ion solutions were compared: 20 mM BaCl₂, 50 mM BaCl₂, and 120 mM CaCl₂. The capsules were then incubated overnight in a buffered solution containing proteins and ions at physiological concentrations at 37°C (Table 1).

After 1, 7, and 14 days of incubation, groups of minimum of 100 microcapsules were quantified for changes in diameter. Images obtained as described were processed using a batch-processing algorithm on Image J (NIH) to calculate microcapsule size. All results are expressed as mean ± SEM. A Mann-Whitney Test was performed to analyze whether the change in microcapsule size was statistically significant (p<0.05).

Effect of gelling ion type and concentration after in vivo transplant

Aqueous solutions of ultra-pure low viscosity mannuronate (UPLVM, NovaMatrix® PRONOVA™) and ultra-pure low viscosity guluronate (UPLVG, NovaMatrix® PRONOVA™) at 2.5% w/v were used to generate alginate microcapsules using a compressed air-driven electrostatic encapsulator (Nisco Engineering AG). Standard settings of 4 psi (pressure), 80 rpm (agitator speed), 30 mm (needle height) and 25 G (needle height) were used. Two different divalent ion solutions were used to crosslink the alginate capsules for 30 minutes: 50 mM BaCl₂ and 120 mM CaCl₂. The capsules were then incubated overnight in 37°C 5% CO₂ incubator in islet media, CMRL 1066 (Cellgro) with 10% newborn calf serum (Sigma Aldrich), supplemented with 5 mM BaCl₂ or CaCl₂, respective to the original crosslinking ion.

The capsules were then transplanted into nondiabetic athymic nude (n=8) or CD1 (n=8) mice, with 1000 capsules transplanted intraperitoneally. After 14 days, the mice were euthanized, the peritoneal cavity was flushed using normal saline, and the capsule diameter was measured by imaging and ImageJ analysis. All animal procedures were conducted under University of California Irvine, Institutional Animal Care and Use Committee approved protocol #2008-2850 for transplant of encapsulated islets in diabetic mice.

Islets were isolated using standard collagenase digestion and gradient purification from Sprague Dawley rats (9). Aqueous solutions of ultra-pure low viscosity mannuronate (UPLVM, NovaMatrix® PRONOVA™) at 2.5% w/v were used to generate alginate microcapsules using a compressed air-driven electrostatic encapsulator (Nisco Engineering AG). Standard settings of 4 psi (pressure), 80 rpm (agitator speed), 30 mm (needle height) and 25 G (needle height) were used. Two different divalent ion solutions were used to crosslink the alginate capsules for 30 minutes: 50 mM BaCl₂ and 120 mM CaCl₂. The capsules were then incubated overnight in 37°C 5% CO₂ incubator in islet media, CMRL 1066 (Cellgro) with 10% newborn calf serum (Sigma Aldrich), supplemented with 5 mM BaCl₂ or CaCl₂, respective to the original crosslinking ion.

Immune competent CD1 mice were made diabetic using streptozotocin, 150 mg/kg, injected intraperitoneally under anesthesia [11]. After 2 consecutive days of blood glucose >350 mg/dL, the diabetic mice received transplant of the encapsulated islets (n=8 per gelling ion type), with 2000 encapsulated islets transplanted intraperitoneally per mouse. Diabetic CD1 mice without any transplant were used as control. After 14 days, the mice were euthanized, the peritoneal cavity was flushed using normal saline, and the islet viability was measured by fluorescein diacetate/propidium iodide fluorescent staining [12]. All animal procedures were conducted under University of California Irvine, Institutional Animal Care and Use Committee approved protocol #2008-2850 (for islet isolation from Sprague Dawley rats) and 2008-2850 (for transplantation).

Statistical analysis

The experiments were repeated three times to ensure that the results obtained were consistent. A Mann-Whitney Test was performed to analyze whether the change in microcapsule size was statistically significant (p<0.05). For transplant studies, a one way ANOVA followed by a post-hoc Tukey HSD test was used to determine statistical significance with a p<0.05 considered statistically significant. All data was reported as mean ± SEM.

Results

Effect of gelling ion type and concentration on microcapsule morphology

After 1 day of incubation in physiological buffer, all barium-gelled capsules shrink in size, whereas calcium-gelled UPLVM capsules, which showed significant increase in diameter. In all groups, capsules polymerized using 50 mM BaCl₂ showed the least amount of change in diameter. This pattern continues all the way to 14-days post incubation (Figure 1). In UPLVM capsules (Figure 1A), there is a significant difference between size changes when gelling with 20 compared 50 mM BaCl₂. In UPLVG capsules (Figure 1B), this difference is only significant until 7 days after incubation in physiological solution.

Effect of gelling ion type and concentration after in vivo transplant

Barium gelled UPLVM capsules show a decrease in diameter

Table 1. Component, concentration, and ions for physiological solution. Physiological solution was made to simulate the environment in which the capsules will be subjected to in the body.

<table>
<thead>
<tr>
<th>Component</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Na⁺</td>
<td>139 mM</td>
</tr>
<tr>
<td>Ca⁺</td>
<td>1.2 mM</td>
</tr>
<tr>
<td>Glucose</td>
<td>5.6 mM</td>
</tr>
<tr>
<td>Urea</td>
<td>5.5 mM</td>
</tr>
<tr>
<td>Albumin</td>
<td>1.4 mM</td>
</tr>
<tr>
<td>Protein</td>
<td>2.2 mM</td>
</tr>
<tr>
<td>PO₄³⁻</td>
<td>1.02 mM</td>
</tr>
<tr>
<td>pH</td>
<td>7.4</td>
</tr>
</tbody>
</table>
when compared to calcium gelled UPLVM capsules, which showed an increase in diameter after transplantation (Figure 2A). In comparison, UPLVG capsules gelled with barium had a larger decrease in diameter, whereas UPLVG capsules gelled with calcium had a decrease in diameter when transplanted into CD1 (immunocompetent) mice but not when transplanted into athymic nude (immunodeficient) mice (Figure 2B). Our results showed that barium gelled UPLVM capsules had significantly less change in capsule size when compared to calcium gelling or UPLVG alginate (Figure 2).

**Effect of gelling ion type and concentration after in vivo transplant of encapsulated islets in diabetic mice**

To determine whether barium or calcium had an effect on the success of transplanted encapsulated islets, barium and calcium gelled encapsulated rat islets in UPLVM alginate were transplanted into immune competent CD1 mice made diabetic using streptozotocin. All recipient mice showed significant reduction in blood glucose, compared to control non-transplanted diabetic mice. Barium-gelled encapsulated islets transplant resulted in significantly lower blood glucose when compared to calcium-gelled encapsulated islets transplant (Figure 3A).

At 14 days, there is no significant difference between islet viability in either type of gelling ion transplanted groups at the time of explant (Figure 3B).

**Discussion**

High mannurate (UPLVM) alginate capsules gelled in a sodium bath exhibited sodium-dependent isotropic swelling not seen in the barium gelled capsules in both in-vitro trials and in-vivo trials. High glucuronic acid alginate (UPLVG) capsules gelled in both barium and calcium did not exhibit swelling in-vitro, but calcium gelled UPLVG capsules exhibited isotropic swelling in athymic nude mice. The ability to optimize alginate microcapsule morphology is an important step in development clinical-grade encapsulation strategies for the treatment of diabetes. Isotropic swelling in alginate microcapsules has profound implications on the morphology of the microcapsules and thus the efficacy of the islets encapsulated within the microcapsules. Isotropic swelling within the alginate microcapsules will decrease the surface area to the volume ratio of the capsule. A higher surface area to volume ratio is needed in these capsules in order to maximize the transfer of nutrients needed to sustain islet viability. A decrease in the surface area to volume ratio decreases the efficacy of nutrient transport with the islets and thus increase the chance of islet hypoxia. Hypoxia would result in a decrease of insulin secreted [13] as well as increase in apoptosis [14]. As noted, islets encapsulated in barium-gelled alginate showed a significantly lower blood sugar in CD1 mice after 14 days compared to calcium-gelled islets. It is also noted that there is no significant difference between the viability of islets between barium-
gelled capsules and calcium-gelled capsules.

The ability to optimize alginate microcapsule morphology is an important step in development of clinical-grade encapsulation strategies for the treatment of diabetes [15,16]. Isotropic swelling noted at physiological sodium ion concentrations is expected to affect microcapsule permeability, which has profound implications for encapsulated islet survival after transplantation. Assays that can evaluate microcapsule permselectivity could be performed to determine the optimal culture conditions to achieve the ideal pore size to maximize transplant success in encapsulated islets [17-19]. The results of this study suggest that alginate composition (specifically, guluronic acid content) and gelling ion type and concentration greatly influence microcapsule morphology and stability. These results indicate that high mannurionate alginate microcapsules and gelling in Ba++ confer significantly better protection from microcapsule swelling [20,21].

Conclusion

The ability to optimize alginate microcapsule morphology is an important step in development of clinical-grade encapsulation strategies for the treatment of diabetes. Since microcapsules are being evaluated for use in transplantation studies, it would be pertinent to develop strategies to mitigate sodium-induced isotropic swelling in alginate microcapsules. Studies are also underway to determine whether sodium-induced isotropic swelling in alginate microcapsules impacts microcapsule stability, permeability and permselectivity. The effects of alginate type, and choice of gelling ion directly influence microcapsule size during in vitro incubation in physiological solutions. Since microcapsules are being evaluated for use in transplantation studies, it would be pertinent to develop strategies to further evaluate barium-gelled alginate UPLVM and UPLVG microcapsules with in vivo studies to evaluate their safety and biocompatibility for islet and stem cell transplantation. However, there remain a variety of parameters to be optimized such as the alginate purification processes, composition, use of engraftable poly-amino acids to achieve modifications to microcapsule surface and configuration, identification of the optimal transplantation site, and identification of the best islet donor before successful translation to human clinical trials can be achieved.

Acknowledgements

The authors gratefully acknowledge funding from the Juvenile Diabetes Research Foundation grant #17-2013-288. The authors also acknowledge support from the Department of Surgery, and the Sue and Bill Gross Stem Cell Center at the University of California, Irvine. The project described was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1 TR000144, for support with statistic analysis. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

References

Dalisay A (2016) The effect of gelling ion on alginate microcapsule size and encapsulated islet efficacy for treating type 1 diabetes


Copyright: ©2016 Dalisay A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.